Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.
A number of other research firms have also recently commented on DCPH. Zacks Investment Research cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. B. Riley initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Friday, February 16th. They set a “buy” rating and a $43.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Deciphera Pharmaceuticals has an average rating of “Buy” and an average target price of $41.14.
Shares of Deciphera Pharmaceuticals (NASDAQ DCPH) opened at $23.62 on Thursday. The company has a market cap of $769.82 and a PE ratio of -3.51. Deciphera Pharmaceuticals has a one year low of $15.15 and a one year high of $29.98.
WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://stocknewstimes.com/2018/03/15/deciphera-pharmaceuticals-dcph-lowered-to-buy-at-bidaskclub.html.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.